Ignite Creation Date:
2025-12-24 @ 11:17 PM
Ignite Modification Date:
2025-12-25 @ 8:56 PM
Study NCT ID:
NCT03481556
Status:
TERMINATED
Last Update Posted:
2022-12-19
First Post:
2018-03-06
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM
Sponsor:
Oncopeptides AB
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-04-12
Start Date Type:
ACTUAL
Primary Completion Date:
2022-02-02
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-02-02
Completion Date Type:
ACTUAL
First Submit Date:
2018-03-06
First Submit QC Date:
None
Study First Post Date:
2018-03-29
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2022-11-08
Results First Submit QC Date:
None
Results First Post Date:
2022-12-19
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-12-14
Last Update Post Date:
2022-12-19
Last Update Post Date Type:
ACTUAL